Table 1 |
||||
|
Characteristics of 196 patients with recent onset IP and in those with and without IR |
||||
|
Variable at baseline |
All pts n = 196 |
IR (HOMA IR ≥ 2.29) n = 118 (60%) |
No IR HOMA IR < 2.29 n = 78 (40%) |
P-value |
|
|
||||
|
Age when first seen (years) † |
49 (40 to 57) |
49 (41 to 56) |
48 (37 to 57) |
0.49 |
|
Male gender |
59 (30%) |
38 (32%) |
21 (27%) |
0.43 |
|
Current smoker |
50 (26%) |
27 (23%) |
23 (29%) |
0.30 |
|
Obese (BMI ≥ 30) |
57 (30%) |
46 (40%) |
11 (15%) |
< 0.001 |
|
On treatment for or diagnosed with DM |
26 (13%) |
16 (14%) |
10 (13%) |
0.88 |
|
Fasting blood glucose (mmol/L) * |
4.7 (4.4 to 5.0) |
4.8 (4.5 to 5.1) |
4.5 (4.3 to 4.8) |
< 0.001 |
|
Fasting insulin (μU) |
12.7 (8.9 to 18.1) |
16.7 (13.2 to 21.6) |
8.2 (6.0 to 9.4) |
< 0.001 |
|
HOMA-IR |
2.7 (1.8 to 3.9) |
3.5 (2.8 to 4.8) |
1.6 (1.2 to 1.9) |
< 0.001 |
|
SBP (mmHg) * |
132 (17) |
135 (17) |
129 (15) |
0.04 |
|
DBP (mmHg) * |
81 (10) |
83 (10) |
79 (9) |
0.01 |
|
On treatment for hypertension |
19 (10%) |
13 (11%) |
6 (8%) |
0.44 |
|
TG (mmol/L) * |
1.4 (0.6) |
1.6 (0.6) |
1.1 (0.5) |
< 0.001 |
|
T.Chol (mmol/L) * |
5.4 (1.1) |
5.5 (1.1) |
5.2 (1.1) |
0.24 |
|
HDL (mmol/L) * |
1.5 (0.4) |
1.5 (0.5) |
1.6 (0.4) |
0.03 |
|
LDL (mmol/L) * |
3.2 (0.9) |
3.3 (0.9) |
3.1 (0.9) |
0.43 |
|
On statin treatment |
11 (6%) |
5 (4%) |
6 (8%) |
0.30 |
|
IP symptom duration (months)† |
6.7 (4.6 to 10.7) |
6.5 (4.5 to 9.9) |
7.0 (4.7 to 11.8) |
0.28 |
|
Age at IP symptom onset |
48 (40 to 56) |
48 (40 to 55) |
48 (36 to 57) |
0.42 |
|
RF positive |
90 (47%) |
63 (55%) |
27 (35%) |
0.01 |
|
ACPA positive |
66 (34%) |
50 (44%) |
16 (21%) |
< 0.001 |
|
Fulfil ACR criteria for RA |
87 (44%) |
58 (49%) |
29 (37%) |
0.10 |
|
Swollen joint count (/51)† |
4 (1 to 7) |
4 (2 to 9) |
4 (1 to 7) |
0.44 |
|
Tender joint count (/51)† |
8 (2 to 18) |
8 (2 to 18) |
9 (3 to 17) |
0.87 |
|
Both swollen & tender (/51)† |
2 (0 to 6) |
2 (0 to 6) |
2 (0 to 5) |
0.96 |
|
CRP (mg/L)† |
10 (7 to 17) |
11 (5 to 21) |
9 (7 to 13) |
0.21 |
|
DAS28CRP † |
3.9 (3.0 to 4.8) |
3.9 (3.0 to 4.9) |
3.9 (3.1 to 4.7) |
0.73 |
|
HAQ† |
0.88 (0.38 to 1.38) |
0.88 (0.38 to 1.68) |
0.88 (0.38 to 1.38) |
0.26 |
|
On steroids prior to baseline assessment |
43 (22%) |
24 (20%) |
19 (24%) |
0.51 |
|
On DMARDs prior to baseline assessment |
105 (54%) |
67 (57%) |
38 (49%) |
0.27 |
|
On MTX prior to baseline assessment |
60 (31%) |
36 (31%) |
24 (31%) |
0.97 |
|
On HCQ prior to baseline assessment |
11 (6%) |
6 (5%) |
5 (6%) |
0.69 |
|
|
||||
|
All data are presented as n (%) except where we indicate that either median (IQR) † or mean (SD) * were used. ACPA, anti-CCP antibody; ACR, American College of Rheumatology; CRP, C-reactive protein; DAS 28CRP , Disease Activity Score calculated using CRP; DBP, diastolic blood pressure; DM, diabetes mellitus; HAQ, Health Assessment Questionnaire; HCQ, hydroxychloroquine; HDL, high density lipoprotein; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; IP, inflammatory polyarthritis; LDL, low density lipoprotein; MTX, methotrexate; RF, rheumatoid factor; SBP, systolic blood pressure; T.chol, total cholesterol; TG, triglycerides |
||||
|
Mirjafari et al. Arthritis Research & Therapy 2011 13:R159 doi:10.1186/ar3476 |
||||
